In this study, we evaluated the combination treatment of EGFR-targeted PDP and EP4 inhibition in the context of ovarian cancer migration, invasion, and metastasis-related cell signaling pathways linked to EP4 and EGFR. This evidence concerns the gene PDP1 and ovarian carcinoma.